Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Treatment for Moderate to Severe Acne

This study has been completed.
Information provided by (Responsible Party):
Medicis Global Service Corporation Identifier:
First received: September 17, 2010
Last updated: November 28, 2011
Last verified: November 2011
To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne

Condition Intervention Phase
Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin

Resource links provided by NLM:

Further study details as provided by Medicis Global Service Corporation:

Primary Outcome Measures:
  • Proportion of patients showing improvement from Baseline and Week 12 [ Time Frame: Week 12 ]

Enrollment: 97
Study Start Date: September 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open Label Combination
Solodyn, Ziana, Triaz FC
Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night

Detailed Description:
A Phase IV, Open-Label Study Evaluating the treatment for Combination Acne Therapy.

Ages Eligible for Study:   12 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • moderate to severe acne, IGA = 3 or 4 (Investigator Global Assessment)

Exclusion Criteria:

  • pregnancy and allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01206348

United States, Alabama
Birmingham, Alabama, United States
United States, California
Santa Monica, California, United States
United States, Delaware
Hockessin, Delaware, United States
United States, Massachusetts
Chestnut Hill, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
United States, Nevada
Henderson, Nevada, United States
United States, North Carolina
High Point, North Carolina, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Utah
Salt Lake City, Utah, United States
Sponsors and Collaborators
Medicis Global Service Corporation
Study Chair: Mary Sanstead, BSN, CCRP Medicis Global Service Corporation
  More Information

Responsible Party: Medicis Global Service Corporation Identifier: NCT01206348     History of Changes
Other Study ID Numbers: MP-0104-28
Study First Received: September 17, 2010
Last Updated: November 28, 2011

Keywords provided by Medicis Global Service Corporation:

Additional relevant MeSH terms:
Benzoyl Peroxide
Dermatologic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Keratolytic Agents processed this record on May 25, 2017